[Advantages and prospects of cell derived decellularized extracellular matrix as tissue engineering scaffolds]
Du Z., Liao J., Wang B., Yu S., Li X.
Narrative Review, published in Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2024) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2024)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 39542617
- PMCID
- PMC11563747
- DOI
- 10.7507/1002-1892.202404114
- Citations
- 2
Abstract (original English)
Objective To review the application of cell derived decellularized extracellular matrix (CDM) in tissue engineering. Methods The literature related to the application of CDM in tissue engineering was extensively reviewed and analyzed. Results CDM is a mixture of cells and their secretory products obtained by culturing cells in vitro for a period of time, and then the mixture is treated by decellularization. Compared with tissue derived decellularized extracellular matrix (TDM), CDM can screen and utilize pathogen-free autologous cells, effectively avoiding the possible shortcomings of TDM, such as immune response and limited sources. In addition, by selecting the cell source, controlling the culture conditions, and selecting the template scaffold, the composition, structure, and mechanical properties of the scaffold can be controlled to obtain the desired scaffold. CDM retains the components and microstructure of extracellular matrix and has excellent biological functions, so it has become the focus of tissue engineering scaffolds. Conclusion CDM is superior in the field of tissue engineering because of its outstanding adjustability, safety, and high bioactivity. With the continuous progress of technology, CDM stents suitable for clinical use are expected to continue to emerge.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.